ClinicalTrials.gg
Not yet recruitingNCT07639645Updated Jun 15, 2026

Intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer

An interventional study of Multimodal intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer in Alzheimer Disease (AD), Unwanted Loneliness and Family Caregivers, sponsored by University of Valencia. Not yet recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by University of Valencia · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.

Planned enrollment
208th of 240
50 · median 258
Started
2026
with 18 others
No phase
66 of 279
17 open now
Primary completion
2026-12
later than 24 of 79 live
Registered
273rd of 279
by date

Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 208th largest by planned enrollment of the 240 interventional ones that give a count, is one of 19 that started in 2026, is one of 66 with no phase, reaches primary completion later than 24 of the 79 other live ones, and was the 273rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Alzheimer Disease with a site in Spain, or all of them as a file.
02

Study summary

The absence of social relationships negatively affects physical, psychological, and social health. In other words, it alters people's quality of life and makes active aging difficult. The investigators have designed a study to reduce unwanted loneliness and improve the living with process of family caregivers of people with Alzheimer disease through multiple interventions (music therapy, health education)

Read the detailed description

This project proposes a multimodal and interdisciplinary intervention aimed at alleviating or reducing unwanted loneliness and improving the living with process of family caregivers of individuals with Alzheimer's disease (AD). In doing so, it seeks to enhance their health and overall quality of life. The intervention will include activities such as health education, physical activity and music therapy.

The interdisciplinary team will also incorporate citizen participation, specifically through the involvement of an individual who has previously been a family caregiver of a person with AD. There is a growing body of evidence indicating that citizen participation in healthcare is highly advisable, as it is expected to improve the quality and relevance of outcomes.

This is a prospective, longitudinal, analytical, and experimental study.

The proposed study will involve different groups and the program will last for a total of 12 weeks. The program will include the following activities:

Physical exercise adapted to the physical conditions of each participant. Total of 12 sessions.

Health education workshops. A total of 12 workshops. These will include group training talks on the following topics: sleep hygiene, diet, and cognitive stimulation, Alzheimer disease, among others.

Music therapy workshops. Through listening to songs, singing, dancing, guided relaxation with music, and group instrumental performance, the enjoyment and expression of feelings will be encouraged. There will be 1 session per week. Total 12 sessions

03

Conditions studied

  • Alzheimer Disease (AD)
  • Unwanted Loneliness
  • Family Caregivers
  • Living With Process

Browse trials for

Keywords

  • unwanted loneliness
  • living with process
  • alzheimer disease
  • family caregiver
  • multicomponent intervention
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Family caregivers of people with Alzheimer's disease (AD).
  • Primary family caregivers who live with the person with AD.
  • The person with AD must be enrolled in one of the adult day care centers where the study is conducted.
  • Ability to communicate in Spanish and/or Valencian.

Exclusion criteria

Exclusion Criteria:

  • Presence of moderate or severe cognitive impairment, mental disorder, significant sensory impairment, disabling chronic illness, or any medical condition that contraindicates participation in any of the study activities.
  • Family caregivers of institutionalized individuals.
  • Family caregivers of people with AD who have died.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Experimental group

    The multimodal interventions includes: 1. Behavioral: Health education for family caregivers of patients with Alzheimer disease with unwanted loneliness Twelve health education workshops will be carried out. These include group training talks on the following topics: sleep hygiene, diet, and cognitive stimulation, among others. 2. Behavioral: Music therapy for community-dwelling individuals with unwanted loneliness Description: Music therapy workshops will implemented. The enjoyment and expression of feelings will encouraged by listening to songs, singing, dancing, guided relaxation with music, and group instrumental performance. One session per week. Total 12 sessions 3. Behavioral: Physical exercise adapted to the physical conditions of each participant. Total of 12 sessions.

    Behavioral: Multimodal intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer

  • No intervention
    No intervention group

    This group will receive the ussual care in the day centers for familiar caregiver

Interventions

  • BehavioralMultimodal intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer

    The multimodal intervention will include these activities: 1. Health education workshops 2. Music therapy sessions 3. Physical exercise adapted to the physical conditions of each participant.

06

What researchers measure

Primary outcomes

  1. Score on the Jong Gierveld Lonelinss Scale

    Loneliness Scale Social isolation will be measured with the Jong Gierveld Loneliness Scale. The final score is the total score for the 11 items, with the lowest possible score being 0 (no loneliness) and the highest being 11 (severe loneliness). Three categories have been proposed based on the score: a score of 0-2 points = no loneliness; a score of 3-8 points = moderate loneliness; and a score of 9-11 points = severe loneliness.

    Time frame: From the beginning of the enrollement until the end of the intervention at 12 weeks

  2. Living with chronic conditions from the family perspective

    Living with LTCs scale from the perspective of the family caregiver (EC- PC- Fam). This is an instrument adapted from the original EC- PC.29-31 The adaptation process of the instrument and prior pilot study have been previously described in detail.23 The validated version has 31 items and 5 domains: (1) acceptance, (2) coping, (3) self- management, (4) integration and (5) adaptation. All the items follow a Likert scale of 5 points answer system, from never or none (0) to always and much (4), except for the items from the acceptance domain, which must be inverted to obtain results such as never or none (4) or always or much (0). The scores range from 0 to 155, with a higher score indicating more positive living with LTCs.

    Time frame: From the enrollment to the end of the intervention at 12 weeks

Secondary outcomes

  1. Score in Goldberg Anxiety and Depression Scale.

    The symptoms of anxiety and depression will be measured with the Goldberg Anxiety and Depression Scale. This is a questionnaire that discriminates between the diagnosis of anxiety and depression and measures their retrospective intensities. It consists of two subscales: one for anxiety and one for depression. Each subscale is composed of 9 dichotomous response items (YES or NO) to determine whether the subject has had any of the indicated symptoms in the last two weeks. The cut-off points are 4 or more items or affirmative responses for the anxiety scale and 2 or more for the depression scale. The higher the score, the greater the severity of the problem, with a maximum possible score of 9 points for each subscale.

    Time frame: From enrollement until the end of the intervention ar 12 weeks

  2. The score in the EuroQQL-5

    The EuroQOL- 5 Dimensions 5- Level version (EQ- 5D- 5L) is an instrument designed to generically measure HRQOL, which can be used by both a healthy population and an individual with pathologies. The instrument developed by the EUROQOL group32 has been validated in many countries, including Spain.33 34 Different versions can be found, and in the present study, the EQ- 5D- 5L was selected due to the increase in the specificity of the responses as compared with the EQ- 5D- 3L. It is a self- administered instrument in which individuals assess their own health, first in a descriptive manner for each of the dimensions (mobility, personal care, everyday activities, pain/ discomfort and anxiety/depression), with five levels, from 0 to 5, and then with a more general Visual Analogical Scale. For the Spanish context, the psycho metric properties of the EQ- 5D- 5L scale were analysed in patients35 with the results indicating a reliability of 0.86.

    Time frame: From enrollement until the end of the intervention at 12 weeks

  3. Score in Zarit Test for caregiver burden

    Zarit test: This scale is included to verify the external validity (divergent validity) of the EC- PC- Fam. This scale, originally named Caregiver Burden Interview, is designed to assess the burden of caregivers of indi viduals with dementia, from the general theory of the items39. It has 22 items that evaluate the negative repercussions on specific areas of daily life associated with caregiving: physical health, psychological health, social activities and economic resources. As opposed to the original, the version validated in Spain40 includes a 5- point Likert scale, for a total score that ranges from 22 to 110. In this study, different cut- off points were proposed: from 22 to 46, without burden; from 47 to 55, with burden and from 56 to 110, intense burden. The scale obtained an internal consistency of 0.91 and test-retest reliability of 0.96.

    Time frame: From enrollement until the end of the intervention at 12 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Marin-Maicas P, Portillo MC, Corchon S, Ambrosio L. Methodological Proposal for the Adaptation of the Living with Long-Term Conditions Scale to the Family Caregiver. Nurs Rep. 2024 Feb 27;14(1):532-544. doi: 10.3390/nursrep14010041. PubMed 38535713 ↗
  • Mafla-Espana MA, Corchon S, Jimeno-de Pedro P, Ibanez-Del Valle V, Cauli O. Social and Mental Health Factors Involved in the Severity of Loneliness in Older Individuals in a Spanish Rural Area. Nurs Rep. 2024 Nov 29;14(4):3737-3753. doi: 10.3390/nursrep14040273. PubMed 39728634 ↗
  • Marin-Maicas P, Ambrosio L, Corchon S, Gonzalez-Moreno J, Portillo MC. Living with long-term conditions: validation of a new instrument for family caregivers in a Spanish-speaking population. BMJ Open. 2024 Sep 20;14(9):e088773. doi: 10.1136/bmjopen-2024-088773. PubMed 39306353 ↗
  • Sanchez-Martinez V, Cauli O, Corchon S. Long-Term Caregiving Impact and Self-Care Strategies in Family Caregivers of People with Neuropsychiatric Disorders: A Mixed-Method Study. Diseases. 2024 Nov 14;12(11):292. doi: 10.3390/diseases12110292. PubMed 39589966 ↗
  • Marin-Maicas P, Corchon S, Ambrosio L, Portillo MC. Living with Long Term Conditions from the Perspective of Family Caregivers. A Scoping Review and Narrative Synthesis. Int J Environ Res Public Health. 2021 Jul 8;18(14):7294. doi: 10.3390/ijerph18147294. PubMed 34299745 ↗
  • Ibanez-Del Valle V, Corchon S, Zaharia G, Cauli O. Social and Emotional Loneliness in Older Community Dwelling-Individuals: The Role of Socio-Demographics. Int J Environ Res Public Health. 2022 Dec 10;19(24):16622. doi: 10.3390/ijerph192416622. PubMed 36554512 ↗
  • Zaharia G, Ibanez-Del Valle V, Cauli O, Corchon S. The Long-Lasting Effect of Multidisciplinary Interventions for Emotional and Social Loneliness in Older Community-Dwelling Individuals: A Systematic Review. Nurs Rep. 2024 Dec 6;14(4):3847-3863. doi: 10.3390/nursrep14040281. PubMed 39728642 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 2 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 10, 2026
StartEst.
Oct 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07639645
Collaborators
The Faculty of Nursing and Podiatry, University of Valencia.
Responsible party
Silvia Corchón Arreche (Principal researcher, University of Valencia) — Principal investigator
First posted
Jun 10, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 15, 2026

Study contacts

Silvia Corchón, PhD
Contact
Silvia.Corchon@uv.es
0034 963864182

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion